Indication
Secondary progressive multiple sclerosis
Secondary progressive multiple sclerosis is an advanced phenotypic phase of multiple sclerosis affecting the central nervous system, occurring in individuals who initially presented with a relapsing-remitting disease course. Read more about Secondary progressive multiple sclerosis
103 drugs 53 manufacturers
Drugs that treat it
Common Secondary progressive multiple sclerosis therapies.
ZEPOSIA STARTER KIT (ozanimod hydrochloride)
TASCENSO ODT (fingolimod lauryl sulfate)
ZEPOSIA STARTER PACK (7-DAY) (ozanimod hydrochloride)
ZEPOSIA STARTER KIT (28-DAY) (ozanimod hydrochloride)
DIMETHYL FUMARATE
FINGOLIMOD (fingolimod HCl)
TERIFLUNOMIDE
DIMETHYL FUMARATE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonSecondary progressive multiple sclerosis is an advanced phenotypic phase of multiple sclerosis affecting the central nervous system, occurring in individuals who initially presented with a relapsing-remitting disease course.
It is clinically defined by an insidious, irreversible accumulation of neurological impairment and physical or cognitive disability that progresses independently of acute attacks.
Pathophysiologically, the disease shifts from predominantly focal, relapsing inflammatory demyelination toward diffuse neurodegeneration, compartmentalized central nervous system inflammation, microglial activation, and axonal loss.
Clinical presentation is further characterized as either active or non-active based on the presence of superimposed relapses or new magnetic resonance imaging activity, as well as with or without progression.
- nih.gov
Secondary progressive multiple sclerosis is an advanced phenotypic phase of multiple sclerosis affecting the central nervous system, occurring in individuals who initially presented with a relapsing-remitting disease course It is clinically defined by an insidious, irreversible accumulation of neurological impairment and physical or cognitive disability that progresses independently of acute attacks
- nationalmssociety.org
Secondary progressive multiple sclerosis is an advanced phenotypic phase of multiple sclerosis affecting the central nervous system, occurring in individuals who initially presented with a relapsing-remitting disease course
- nih.gov
It is clinically defined by an insidious, irreversible accumulation of neurological impairment and physical or cognitive disability that progresses independently of acute attacks
- massgeneralbrigham.org
Pathophysiologically, the disease shifts from predominantly focal, relapsing inflammatory demyelination toward diffuse neurodegeneration, compartmentalized central nervous system inflammation, microglial activation, and axonal loss Clinical presentation is further characterized as either active or non-active based on the presence of superimposed relapses or new magnetic resonance imaging activity, as well as with or without progression
- sanofi.com
Pathophysiologically, the disease shifts from predominantly focal, relapsing inflammatory demyelination toward diffuse neurodegeneration, compartmentalized central nervous system inflammation, microglial activation, and axonal loss
- nationalmssociety.org
Pathophysiologically, the disease shifts from predominantly focal, relapsing inflammatory demyelination toward diffuse neurodegeneration, compartmentalized central nervous system inflammation, microglial activation, and axonal loss
- nih.gov
Clinical presentation is further characterized as either active or non-active based on the presence of superimposed relapses or new magnetic resonance imaging activity, as well as with or without progression
Personalize your experience
Follow Secondary progressive multiple sclerosis and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.